Clinic
Weeks Medical Center
Weeks Medical Center was paid $3.48M by Medicaid between Jan 2018 and Dec 2024, across 104 billing codes. Its largest line is 99282, Emergency department visit for the evaluation and management, low to moderate severity — 19% of everything it billed.
33Billing provider infoWEEKS MEDICAL CENTER
LANCASTER, NH 03584
LANCASTER, NH 03584
33aNPI1265536718assigned 09/12/2006
33bProvider typeRural Health Clinic/Center
28Total paid$3.48M
24GClaims99,863
24DCodes billed104
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Rural Health Clinic/Center providers in New Hampshire
Rank by total paid#3 of 8
Median peer was paid$2.18M
This provider vs. median1.6×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 12,101 | $285K | |
| 2019 | 15,736 | $422K | |
| 2020 | 21,154 | $784K | |
| 2021 | 24,407 | $951K | |
| 2022 | 18,769 | $773K | |
| 2023 | 4,797 | $144K | |
| 2024incomplete | 2,899 | $122K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 19% | 4,140 | 3,299 | $659K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 16% | 3,305 | 2,260 | $551K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 11% | 2,186 | 1,245 | $389K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 7.8% | 3,485 | 2,257 | $271K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 5.7% | 4,256 | 2,548 | $199K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 4.5% | 964 | 218 | $158K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 4.4% | 2,398 | 659 | $154K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.5% | 1,948 | 1,457 | $86K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.7% | 857 | 571 | $58K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.6% | 1,110 | 659 | $56K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.6% | 883 | 676 | $55K |
| 80306 | 1.4% | 4,853 | 2,582 | $49K |
92 more codes
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.4% | 71 | $47K |
| 71046 | Radiologic examination, chest; 2 views | 1.2% | 721 | $43K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 1.2% | 3,687 | $43K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.2% | 527 | $41K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.2% | 258 | $40K |
| 80053 | Comprehensive metabolic panel | 1.1% | 7,493 | $40K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 1.1% | 1,635 | $37K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 1.1% | 310 | $37K |
| 87631 | <1% | 407 | $34K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,367 | $32K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 8,571 | $31K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 301 | $28K |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 1,561 | $25K |
| 80061 | Lipid panel | <1% | 2,239 | $25K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 492 | $23K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 221 | $21K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,990 | $19K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 1,150 | $18K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 132 | $14K |
| 73630 | <1% | 163 | $13K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,556 | $12K |
| 71045 | Radiologic examination, chest; single view | <1% | 423 | $12K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,592 | $12K |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 115 | $11K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,163 | $11K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 476 | $11K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | <1% | 110 | $8K |
| 90682 | <1% | 311 | $8K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 290 | $7K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 637 | $6K |
| 36415 | Collection of venous blood by venipuncture | <1% | 11,416 | $6K |
| 83735 | <1% | 1,314 | $5K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 103 | $5K |
| 84484 | <1% | 1,440 | $5K | |
| 80076 | <1% | 773 | $5K | |
| 87081 | <1% | 913 | $4K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 433 | $4K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 94 | $4K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 879 | $3K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 142 | $3K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 16 | $3K |
| 81001 | <1% | 1,649 | $3K | |
| 81025 | <1% | 499 | $3K | |
| J3490 | Unclassified drugs | <1% | 1,407 | $3K |
| 73610 | <1% | 19 | $2K | |
| 80305 | <1% | 231 | $2K | |
| 83690 | <1% | 537 | $2K | |
| 90670 | <1% | 311 | $2K | |
| 82607 | <1% | 156 | $1K | |
| 86140 | <1% | 456 | $1K | |
| 85610 | <1% | 569 | $1K | |
| 81002 | <1% | 872 | $1K | |
| 97162 | <1% | 15 | $1K | |
| 87276 | <1% | 162 | $1K | |
| 85027 | <1% | 262 | $1K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 58 | $1K |
| 87275 | <1% | 169 | $1K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 16 | $1K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 481 | $906.93 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 44 | $849.85 |
| 90715 | <1% | 51 | $730.17 | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 59 | $704.38 |
| 82728 | <1% | 47 | $592.26 | |
| 90837 | Psychotherapy session, about an hour | <1% | 45 | $563.05 |
| 85651 | <1% | 150 | $397.39 | |
| 87077 | <1% | 85 | $366.37 | |
| 83655 | <1% | 31 | $348.00 | |
| 83550 | <1% | 47 | $322.09 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 359 | $315.66 |
| 87186 | <1% | 72 | $309.27 | |
| 90651 | <1% | 111 | $304.57 | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 12 | $279.51 |
| 82746 | <1% | 22 | $265.68 | |
| 82948 | <1% | 25 | $255.22 | |
| 83540 | <1% | 49 | $245.00 | |
| 90473 | <1% | 26 | $238.39 | |
| G0008 | Administration of influenza virus vaccine | <1% | 13 | $215.33 |
| 80050 | General health panel | <1% | 25 | $199.80 |
| 84439 | <1% | 34 | $192.98 | |
| 84703 | <1% | 32 | $175.41 | |
| 86803 | <1% | 14 | $173.32 | |
| 85018 | <1% | 74 | $153.68 | |
| 90686 | <1% | 863 | $145.38 | |
| 87070 | <1% | 12 | $73.94 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 35 | $71.25 |
| 85652 | <1% | 34 | $64.38 | |
| 90723 | 0% | 130 | $0.00 | |
| 90680 | 0% | 69 | $0.00 | |
| 90633 | 0% | 188 | $0.00 | |
| 90648 | 0% | 266 | $0.00 | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 0% | 48 | $0.00 |
| 90734 | 0% | 45 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLANDRY, SUZANNE (VP COMPLIANCE AND RISK MANAGEMENT)
| Provider | Location | Paid |
|---|---|---|
| Androscoggin Valley Hospital, INC. | Berlin, NH | $8.28M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.